TABLE 2.

Clinical performance of three immunoassays

		Clinical diagnosis				Sensitivity		Specificity
		Positive		Negative		(95% CI)		(95% CI)
		D ≥ 14	D < 14	Healthy	Other	Total	D ≥ 14	Total	Healthy	Other
		(n = 126)	(n = 47)	(n = 98)	(n = 53)	(n = 173)	(n = 126)	(n = 151)	(n = 98)	(n = 53)
Abbott Quant	Pos	123	43	1	0	96	97.6	99.3	99.0	100
	Neg	3	4	97	53	(91.8–98.4)	(93.2–99.5)	(96.4–100.0)	(94.4–100.0)	(93.3–100.0)
DiaSorin TrimericS	Pos	122	40	0	0	93.6	96.8	100	100	100
	Neg	4	7	98	53	(88.9–96.8)	(92.1–99.1)	(97.6–100.0)	(96.3–100.0)	(93.3–100.0)
Roche S	Pos	123	43	0	0	96	97.6	100	100	100
	Neg	3	4	98	53	(91.9–98.4)	(93.2–99.5)	(97.6–100.0)	(96.3–100.0)	(93.0–100.0)
Genscript cPass	Pos	123	41	NT	NT	94.8	97.6	NT	NT	NT
	Neg	3	6	NT	NT	(90.4–97.6)	(93.2–99.5)	NT	NT	NT

Abbreviations: Abbott Quant, Abbott SARS‐CoV‐2 IgG II Quant; D, days after onset of symptom; DiaSorin TrimericS, DiaSorin LIAISON SARS‐CoV‐2 TrimericS IgG; Genscript cPass, Genscript cPass SARS‐CoV‐2 Neutralization Antibody Detection Kit;NT, not tested; Other, other infection; Roche S, Roche Elecsys anti‐SARS‐CoV‐2 S.